David P. Bender, MD

Portrait
Professor of Obstetrics and Gynecology - Gynecologic Oncology
NRG Oncology Principal Investigator

Contact Information

Primary Office
31507 PFP
200 Hawkins Dr
Iowa City, IA 52242
319-356-2015

Education

BA, Bowdoin College, Brunswick, Maine
MD, Medicine, Finch University of the Health Sciences/The Chicago Medical School, North Chicago, Illinois
Resident, Obstetrics and Gynecology & Reproductive Sciences, Magee-Women's Hospital, University Health Center of Pittsburgh, Pittsburgh, Pennsylvania
Fellow, Department of OB/GYN, University of Louisville School of Medicine
Fellow, Gynecologic Surgery, University of Iowa Hospitals and Clinics
Fellow, Gynecologic Oncology, University of Iowa Hospitals and Clinics

Licensure and Certifications

Subspecialty Certification in Gynecologic Oncology
Board Certification in Obstetrics & Gynecology

Publications

Ahmed, A., Deng, W., Tew, W., Bender, D., Mannel, R. S., Littell, R. D., DeNittis, A. S., Edelson, M., Morgan, M., Carlson, J., Darus, C. J., Fleury, A. C., Modesitt, S., Olawaiye, A., Evans, A. & Fleming, G. F. (2018). Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study. Gynecol Oncology, 150(2), 300-305. PMID: 29807694.

Aghajanian, C., Filiaci, V., Dizon, D. S., Carlson, J. W., Powell, M. A., Secord, A. A., Tewari, K. S., Bender, D. P., O'Malley, D. M., Stuckey, A., Gao, J., Dao, F., Soslow, R. A., Lankes, H. A., Moore, K. & Levine, D. A. (2018). A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gyncol Oncolo, 150(2), 274-281. PMID: 29804638.

Armer, J. S., clevenger, L., Davis, L. Z., Cuneo, M., Thacker, P. H., Goodheart, M. J., Bender, D. P., Dahmoush, L., Sood, A. K., Cole, S. W., Slavich, G. M. & Lutgendorf, S. K. (2018). Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. Cancer [Epub ahead of print]. PMID: 29905941.

Horowitz, N. S., Larry Maxwell, G., Miller, A., Hamilton, C. A., Rungruang, B., Rodriguez, N., Richard, S. D., Krivak, T. C., Fowler, J. M., Mutch, D. G., Van Le, L., Lee, R. B., Argenta, P., Bender, D., Tewari, K. S., Gershenson, D., Java, J. J. & Bookman, M. A. (2018). Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecl Oncol, 148(1), 49-55. PMID: 29174555.

Cuneo, M. G., Schrepf, A., Slavich, G. M., Thacker, P. H., Goodheart, M., Bender, D., Cole, S. W., Sood, A. K. & Lutgendorf, S. K. (2017). Diurnal cortisol rhythms, fatigue and psychosocial factors in five-year survivors of ovarian cancer. Psychoneuroendocrinology, 84, 139-142. PMID: 28711723.

Christensen, D. K., Armaiz-Pena, G. N., Ramirez, E., Matsuo, K., Zimmerman, B., Zand, B., Shinn, E., Goodheart, M. J., Bender, D., Thacker, P. H., Ahmed, A., Penedo, F. J., DeGeest, K., Mendez, L., Domann, F., Sood, A. K. & Lutgendorf, S. K. (2016). SSRI use and clinical outcomes in epithelial ovarian cancer. Oncotarget, 7(22), 33179-91. PMID: 27121207.

Davis, L. Z., Slavich, G. M., Thacker, P. H., Goodheart, M. J., Bender, D. P., Dahmoush, L., Farley, D. M., Markon, K. E., Penedo, F. J., Lubaroff, D. M., Cole, S. W., Sood, A. K. & Lutgendorf, S. K. (2015). Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer. Cancer, 121(19), 3543-50. PMID: 26096769.

Bender, D., Sill, M. W., Lankes, H. A., Reyes, H. D., Darus, C. J., Delmore, J. E., Rotmensch, J., Gray, H. J., Mannel, R. S., Schilder, J. M., Hunter, M. I., McCourt, C. K., Samuelson, M. I. & Leslie, K. K. (2015). A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol, 138(3), 507-12. PMID: 26186911.

Stephan, J. M., Goodheart, M. J., McDonald, M., Hansen, J., Reyes, H. D., Button, A. & Bender, D. (2015). Robotic surgery in super-morbidly obese patients with endometrial cancer. Am J Obstet Gynecol, 213(1), 49.e1-8. PMID: 25644437.

Hansen, J., Stephan, J. M., Freesmeier, M., Bender, D., Button, A. & Goodheart, M. J. (2015). The effect of weight-based chemotherapy dosing in a cohort of gynecologic oncology patients. Gyncol Oncol, 138(1), 154-8. PMID: 25958318.

Coleman, R. L., Sill, M. W., Thaker, P. H., Bender, D. P., Street, D., McGuire, W. P., Johnston, C. M. & Rotmensch, J. (2015). A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol, pii: S0090-8258(15), 00795-7. PMID: 25887099.

Kunos, C., Deng, W., Dawson, D., Lea, J. S., Zanotti, K. M., Gray, H. J., Bender, D. P., Guaglianone, P. P., Carter, J. S. & Moore, K. N. (2015). A Phase I-II Evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix: An NRG Oncology/Gynecologic Oncology Group Study. Int J Gynecol Cancer, 25(3), 484-92. PMID: 25594147.

Schrepf, A., Thaker, P. H., Goodheart, M. J., Bender, D., Slavich, G. M., Dahmoush, L., Penedo, F., DeGeest, K., Mendez, L., Labaroff, D. M., Cole, S. W., Sood, A. K. & Lugendorf, S. K. (2015). Diurnal cortisol and survival in epithelial ovarian cancer. Psychoneuroendocrinology, 53, 256-67. PMID: 25647344.

Alvarez, R. D., Sill, M. W., Davidson, S. A., Muller, C. Y., Bender, D. P., Debernardo, R. L., Behbakht, K. & Huh, W. K. (2014). A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group study. Gynecol Oncol, 133(3), 433-8. PMID: 24708919.

Stephan, J. M., Hansen, J., Samuelson, M., McDonald, M., Chin, Y., Bender, D., Reyes, H. D., Button, A. & Goodheart, M. J. (2014). Intra-operative frozen section results reliably predict final pathology in endometrial cancer. Gynecol Oncol..

Lutgendorf, S. K., Slavich, G. M., Degeest, K., Goodheart, M., Bender, D., Thaker, P. H., Penedo, F., Zimmerman, B., Lucci III, J., Mendez, L., Collins, K. & Sood, A. K. (2013). Non-cancer life stressors contribute to impaired quality of life in ovarian cancer patients. Gynecol Oncol, 131(3), 667-73. PMID: 24096110.

Clevenger, L., Schrepf, A., Degeest, K., Bender, D., Goodheart, M., Ahmed, A., Dahmoush, L., Penedo, F., Lucci III, J., Thaker, P. H., Mendez, L., Sood, A. K., Slavich, G. M. & Lutgendorf, S. K. (2013). Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis. Cancer, 119(17), 3234-41. PMID: 23797955.

Nadkarni, N. J., Geest, K. D., Neff, T., Young, B. D., Bender, D. P., Ahmed, A., Smith, B. J., Button, A. & Goodheart, M. J. (2013). Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer. Cancer letters, 331(1), 99-104. PMID: 23268330.

Schrepf, A., Clevenger, L., Christensen, D., De Geest, K., Bender, D. P., Ahmed, A., Goodheart, M. J., Dahmoush, L., Penedo, F., Lucci III, J. A., Ganjei-Azar, P., Mendez, L., Markon, K., Lubaroff, D. M., Thaker, P. H., Slavich, G. M., Sood, A. K. & Lutgendorf, S. K. (2013). Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: Relationships with depression, fatigue, and disability. Brain Behav Immun, 30, Supplement, S126-S134.

Clevenger, L., Schrepf, A., Christensen, D., De Geest, K., Bender, D. P., Ahmed, A., Goodheart, M. J., Penedo, F., Lubaroff, D. M., Sood, A. K. & Lutgendorf, S. K. (2012). Sleep disturbance, cytokines, and fatigue in women with ovarian cancer. Brain, Behavior, and Immunity, 26(7), 1037-44. PMID: 22543257.

Engle, D. B., Connor, J. P., Morris, P. C., Bender, D. P., De Geest, K., Ahmed, A. & Goodheart, M. J. (2012). Intraoperative autologous blood transfusion use during radical hysterectomy for cervical cancer: long-term follow-up of a prospective trial. Archives of gynecology and obstetrics, 286(3), 717-21. PMID: 22569711.

Lutgendorf, S. K., De Geest, K., Bender, D., Ahmed, A., Goodheart, M. J., Dahmoush, L., Zimmerman, M., Penedo, F. J., Lucci III, J. A., Genjei-Azar, P., Thaker, P. H., Mendez, L., Lubaroff, D. M., Slavich, G. M., Cole, S. W. & Sood, A. K. (2012). Social Influences on Clinical Outcomes of Patients with Ovarian Cancer. Journal of Clinical Oncology, 30(23), 2885-90.

Shelton, D. N., Fornalik, H., Neff, T., Park, S., Bender, D., De Geest, K., Liu, X., Xie, W., Meyerholz, D. K., Engelhardt, J. F. & Goodheart, M. J. (2012). The Role of LEF1 in Endometrial Gland Formation and Carcinogenesis. PLoS One, 7(7), e40312.

Shamshirsaz, A., Buekers, T., De Geest, K., Bender, D. P., Zamba, G. & Goodheart, M. J. (2011). A single-institution evaluation of factors important in fallopian tube carcinoma recurrence and survival. International Journal of Gynecological Cancer, 21(7), 1232-40.

Lutgendorf, S. K., De Geest, K., Dahmoush, L., Farley, D., Penedo, F., Bender, D. P., Goodheart, M. J., Buekers, T. E., Mendez, L., Krueger, G., Clevenger, L., Lubaroff, D. M., Sood, A. K. & Cole, S. W. (2011). Social Isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. Brain Behav Immun, 25(2), 250-5.

Lutgendorf, S. K., Mullen-Houser, E., Russell, D., De Geest, K., Jacobson, G., Hart, L., Bender, D. P., Anderson, B., Buekers, T. E., Goodheart, M. J., Antoni, M. H., Sood, A. K. & Lubaroff, D. M. (2010). Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach. Brain, Behavior and Immunity, 24(8), 1231-40.

Weinrib, A. Z., Sephton, S. E., De Geest, K., Penedo, F., Bender, D. P., Zimmerman, B., Kirschbaum, C., Sood, A. K., Lubaroff, D. M. & Lutgendorf, S. K. (2010). Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer. Cancer, 116(18), 4410-9.

Modesitt, S. C., Sill, M., Hoffman, J. S. & Bender, D. P. (2008). A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecologic oncology, 109(2), 182-6. PMID: 18295319.

Covens, A., Blessing, J., Bender, D. P., Mannel, R. & Morgan, M. (2006). A Phase II Evaluation of Tirapazamine plus Cisplatin in the Treatment of Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology, 100(3), 586-590.

Han, L. Y., Landen, C. N., Kamat, A. A., Lopez, A., Bender, D. P., Mueller, P., Schmandt, R., Gershenson, D. M. & Sood, A. K. (2006). Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24(5), 755-61. PMID: 16380413.

Sharma, N. K., Sorosky, J. I., Bender, D. P., Fletcher, M. S. & Sood, A. K. (2005). Malignant Mixed Mullerian Tumor (MMMT) of the Cervix. Gynecologic Oncology, 97, 442-445. PMID: 15863143.

Bender, D. P., Sorosky, J. I., Buller, R. E. & Sood, A. K. (2003). Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma. American journal of obstetrics and gynecology, 189(1), 113-7. PMID: 12861147.

Bender, D. P., Cooper, B. C., Sorosky, J. I. & Sood, A. K. (2003). Placental growth factor (PlGF) is a novel prognostic marker in ovarian cancer.

Bender, D. P., Mahavni, V., Kim, S., Zogg, M., Ritchie, J. & Buller, R. E. (2002). Novel sites and markers enhance the detection of x-inactivation in ovarian cancer.

Bender, D. P., Sood, A. K., Sorosky, J. I., Anderson, B. A. & Buller, R. E. (2002). The prognostic value of a pretreatment serum CA-125 in cervical adenocarcinoma.

Lowe, M. P., Bender, D. P., Sood, A. K., Davis, W., Syrop, C. H. & Sorosky, J. I. (2002). Delivery of Twin Gestations Following Conservative Treatment of Endometrial Cancer and Assisted Reproduction. Fertility and Sterility, 77, 188-189.

Taylor, D. D., Bender, D. P., Gerçel-Taylor, C., Stanson, J. & Whiteside, T. L. (2001). Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients. British journal of cancer, 84(12), 1624-9. PMID: 11401315.

Bender, D. P., Sood, A. K., Sorosky, J. I., Anderson, B. A. & Butler, R. E. (2001). The value of pretreatment serum CA-125 in cervical adenocarcinoma.

Bender, D. P., Sood, A. K. (2001). Chemoradiation for the Treatment of Cervical Cancer: A New Paradigm. Postgraduate Obstetrics and Gynecology, 21, 1-6.

Friebe-Hoffmann, U., Bender, D. P., Sims, C. J. & Rauk, P. N. (2000). Candida albicans chorioamnionitis associated with preterm labor and sudden intrauterine demise of one twin. A case report. The Journal of reproductive medicine, 45(4), 354-6. PMID: 10804496.

Bender, D. P., Makhija, S., Taylor, D. D. & Gercel-Taylor, C. (2000). Cisplatin and taxol-induced caspase-3 activity in ovarian cancer cell monolayer and spheroids.

Bender, D. P., Sullivan, S., Gercel-Taylor, C. & Taylor, D. D. (2000). Modulation of T-cell receptor zeta chain expression in pregnancy.

Bender, D. P., Gercel-Taylor, C. & Taylor, D. D. (2000). Isolation of a soluble inhibitor of zeta chain expression in gynecologic malignancies.

Resnik, E., Bender, D. P. (1996). Syndrome of Inappropriate Antidiuretic Hormone Secretion in Papillary Serous Surface Carcinoma of the Peritoneum. Journal of Surgical Oncology, 61, 63-65.

Clodfelter, S. A., Doede, T. M., Brennan, B. A., Nagle, J. K., Bender, D. P., Turner, W. A. & Lapunzina, P. M. (1994). Luminescent Metal-Metal Bonded Exciplexes Involving Tetrakis (mu-diphosphito) diplatinate (II) and Thallium (I). Journal of the American Chemical Society, 116.

Bender, D. P., Nagle, J. K. (1994). Metal-Metal Interactions of Aqueous Lead (II) and Tin (II) Ions with the Ground and Excited States of Tetrakis (mu-diphosphito) diplatinate (II). Inorganica Chimica Acta, 225, 201-205.